Cargando…
Urotensin-II Immunoreactivity in Normolipidemic and Hyperlipidemic New Zealand White Rabbits Following Balloon Angioplasty and Stenting
Treatment for symptomatic atherosclerosis is being carried out by balloon mediated angioplasty, with or without stent implantation, more and more frequently. Although advances with the development of drug eluting stents have improved prognosis, restenosis is still the most limiting factor for this t...
Autores principales: | Bousette, Nicolas, Chouiali, Fazila, Ohlstein, Eliot H., Douglas, Stephen A., Giaid, Adel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Master Publishing Group
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614616/ https://www.ncbi.nlm.nih.gov/pubmed/23675019 |
Ejemplares similares
-
Potential Clinical Implications of the Urotensin II Receptor Antagonists
por: Tsoukas, Philip, et al.
Publicado: (2011) -
A closer look at the role of urotensin II in the metabolic syndrome
por: Barrette, Pierre-Olivier, et al.
Publicado: (2012) -
Urotensin II Enhances Advanced Aortic Atherosclerosis Formation and Delays Plaque Regression in Hyperlipidemic Rabbits
por: Yu, Qingqing, et al.
Publicado: (2023) -
Postprandial triglyceride response in normolipidemic, hyperlipidemic and obese subjects – the influence of polydextrose, a non-digestible carbohydrate
por: Tiihonen, Kirsti, et al.
Publicado: (2015) -
A review of the effect of omega-3 polyunsaturated fatty acids on blood triacylglycerol levels in normolipidemic and borderline hyperlipidemic individuals
por: Leslie, Michael A., et al.
Publicado: (2015)